This study is testing a new medicine, *Sutetinib Maleate*, for a type of lung cancer called *non-small cell lung cancer (NSCLC)*. NSCLC can sometimes be caused by changes in a gene called *EGFR*, which makes a protein that helps cells grow. When this gene changes, it can make cancer cells grow uncontrollably. The study wants to see if Sutetinib Maleate can help stop this cancer growth in patients with these uncommon EGFR changes.
- Eligibility: People aged 18-75 with specific lung cancer and a life expectancy of more than 3 months.
- Exclusions: Those who have taken similar cancer treatments or have certain health issues cannot join.
- Commitment: The study will involve multiple visits and requires participants to take capsules regularly.
If you are interested in participating, you need to be able to swallow capsules and have no recent major surgeries or infections. This study will help researchers understand if Sutetinib Maleate is a safe and effective treatment for NSCLC with uncommon EGFR mutations.
How understandable was the trial content above?
Hard to understand
Easy to understand